Sept 2 (Reuters) - Zymeworks ZYME.O said on Tuesday it will stop developing its experimental cancer drug after early-stage trial results showed the treatment was unlikely to meet the company's goals as a standalone therapy.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Krishna Chandra Eluri)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.